BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/26/2025 10:16:45 AM | Browse: 90 | Download: 444
 |
Received |
|
2024-10-14 09:14 |
|
Peer-Review Started |
|
2024-10-14 09:14 |
|
First Decision by Editorial Office Director |
|
2024-11-28 09:40 |
|
Return for Revision |
|
2024-11-28 09:40 |
|
Revised |
|
2024-12-20 16:51 |
|
Publication Fee Transferred |
|
2024-12-27 14:17 |
|
Second Decision by Editor |
|
2025-02-27 02:40 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-02-27 08:44 |
|
Articles in Press |
|
2025-02-27 08:44 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-03-13 08:30 |
|
Publish the Manuscript Online |
|
2025-03-26 10:16 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Combining anti-PD-1 antibodies with surufatinib for gastrointestinal neuroendocrine carcinoma: Two cases report and review of literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Lou-Lu Gao, Dong-Ni Gao, Hong-Tu Yuan, Wen-Qiang Chen, Jing Yang and Jie-Qiong Peng |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jie-Qiong Peng, Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, No. 440 Jiyan Road, Jinan 250117, Shandong Province, China. 15589116608@163.com |
| Key Words |
Gastrointestinal neuroendocrine carcinoma; Immune checkpoint inhibitors; Angiogenesis inhibitors; Combination therapy; Case report |
| Core Tip |
Effective treatment options for metastatic gastrointestinal neuroendocrine carcinomas (GI-NECs) are limited after chemotherapy failure. This study presents the cases of two patients with metastatic rectal and duodenal neuroendocrine carcinomas who achieved sustained remission and long-term survival through a combination of antiangiogenic targeted therapy and anti-PD-1 immunotherapy. These cases highlight the potential of this combination as a posterior-line treatment for GI-NECs, offering new insights into their management. |
| Publish Date |
2025-03-26 10:16 |
| Citation |
Gao LL, Gao DN, Yuan HT, Chen WQ, Yang J, Peng JQ. Combining anti-PD-1 antibodies with surufatinib for gastrointestinal neuroendocrine carcinoma: Two cases report and review of literature. World J Clin Oncol 2025; 16(4): 102297 |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i4/102297.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i4.102297 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
